These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25308916)

  • 1. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
    Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
    Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
    Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
    Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
    Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
    PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
    Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
    J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.
    Russell MR; Levin K; Rader J; Belcastro L; Li Y; Martinez D; Pawel B; Shumway SD; Maris JM; Cole KA
    Cancer Res; 2013 Jan; 73(2):776-84. PubMed ID: 23135916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.
    Francisco R; Pérez-Perarnau A; Cortés C; Gil J; Tauler A; Ambrosio S
    Cancer Lett; 2012 May; 318(1):42-52. PubMed ID: 22186300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
    Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
    Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
    Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
    Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.